26 isn’t just another year in market access — it’s a turning point.

In this episode of Let’s Talk Rare, P4A dives into the trends that are about to reshape how rare disease therapies reach patients across Europe — and trust us, the ground is moving.

Policy is back in the spotlight. With the EU Pharmaceutical Strategy resurfacing, the big question is:
How do we reward innovation and keep medicines affordable? The balance is shifting, and everyone — manufacturers, regulators, patients — will feel it.

Meanwhile, AI is no longer hype. It’s influencing research, pricing models, even HTA decisions. Faster insights, smarter systems… but also tough questions about transparency, trust, and who — or what — is really making the call.

And patients? They’re not sitting on the sidelines anymore. Patient engagement is becoming central to access decisions, pushing HTA bodies toward more inclusive frameworks, real-world perspectives, and maybe even a rethink of traditional ICER thresholds.

Bottom line:
2026 is a year of change — and serious opportunity. The winners will be the ones who adapt early.

🎧 Tune in to P4A’s Let’s Talk Rare to get ahead of the trends shaping the future of market access in Europe.